AUTHORS
Amy E. Pierre, MSN, ANP-BC, Benji Wagner, MS2, Caitlin Dwyer3, Gene G. Ho, MPH4
AFFILIATIONS
1 Flatiron Health, New York, New York, United States
2 Flatiron Health, Durham, North Carolina, United States
3 Flatiron Health, New York, New York, United States
4 Flatiron Health, New York, New York, United States
ABSTRACT
Background
Multiple myeloma (MM) is an incurable malignancy with heterogeneous outcomes. While cytogenetic risk stratification guides prognosis at diagnosis, a subset of patients experience early disease progression termed functional high-risk multiple myeloma (FHRMM). These patients are not well-captured by conventional cytogenetic risk models, and the clinical, molecular, and social determinants that are associated with FHRMM remain incompletely understood. The objective of this study is to characterize the baseline clinical and molecular attributes and socioeconomic status (SES) of patients with FHRMM and evaluate their treatment patterns and survival outcomes compared to non-FHRMM patients to improve early risk identification and personalized management.
Methods
This retrospective study used the electronic health record-derived United States Flatiron Health Research Database. Eligible patients were newly diagnosed with MM (NDMM) and received ≥1 line of therapy by October 31, 2024. FHRMM was defined as documented progression or death within 18 months of first line therapy (1L). Study population was characterized by age, sex, race/ethnicity, International Staging System (ISS), Eastern Cooperative Oncology Group performance status (ECOG PS), cytogenetic abnormalities (del[17p], del[1p32], t[4;14], t[14;16], t[14;20], 1q gain), presence of extramedullary disease (EMD), serum biomarkers (beta-2 microglobulin, albumin, lactate dehydrogenase, M-spike, hemoglobin, platelets, calcium), renal function (estimated glomerular filtration rate [eGFR], creatinine), treatment intensity (doublet through quadruplet), autologous stem cell transplant (ASCT) use, and an area-level SES measure based on the Yost index. Univariate modified Poisson regression with robust sandwich variance estimators was used to assess patient characteristics associated with FHRMM status. Median 1L real-world progression-free survival (rwPFS1) was calculated for use of ASCT and treatment intensity among FHRMM patients. Multivariate Cox models assessed post-progression survival and post-progression PFS (time from first to second progression/death) in the overall cohort. Sensitivity analyses excluded patients with high-risk chromosomal abnormalities (HRCAs).
Results
Among 15,404 eligible patients with NDMM, 3209 (21%) met criteria for FHRMM. FHRMM was associated with ECOG PS scores ≥1 (Prevalence Ratio [PR] range: PR=1.23 [95% CI: 1.12-1.36] to PR=1.40 [CI: 1.26-1.56]), advanced stage (ISS Stage II: PR=1.27 [CI: 1.14-1.40]; Stage III: PR=1.48 [CI: 1.34-1.63]) and EMD (PR=1.14 [CI: 1.01-1.28]. In addition to HRCA, other clinical factors associated with FHRMM were abnormal hemoglobin (PR=1.38 [CI: 1.25-1.52]), impaired eGFR (PR=1.13 [CI: 1.04-1.23]), abnormal calcium (High calcium PR=1.13 [CI: 1.03-1.23]; Low calcium PR=1.10 [CI: 1.00-1.22]) and a low platelet count (PR=1.31 [CI: 1.21-1.42]). Black race was associated with an increased likelihood of FHRMM (PR=1.13 [CI: 1.04-1.22]) as well as age ≥75 (PR=1.16 [CI: 1.02-1.32]) relative to White and 19-50 year old patients. Patients in the highest SES quintile were less likely to be FHRMM (PR=0.90 [CI: 0.81-1.00]) than those in the lowest quintile. FHRMM patients who received ASCT within 6 months had a longer median PFS1 than those who did not (11 months [CI: 10-12]; 6.0 months [CI: 5.5-6.2]). Patients on quadruplet therapy had a longer median PFS1 compared with those on doublet therapy (9.8 months [CI: 8.6-11]; 8.0 months [CI: 7.7-8.5]). FHRMM was also associated with worse post-progression survival (HR=1.13 [CI: 1.06-1.20]) and worse post-progression PFS (HR=1.17 [1.09-1.25]).
Sensitivity analyses performed on 2804 FHRMM patients without HRCA demonstrated remarkably similar estimates across association and outcomes analyses.
Conclusions
In this large real-world cohort of NDMM patients, FHRMM was associated with distinct clinical, socioeconomic and demographic characteristics identifiable at diagnosis. FHRMM patients experienced worse post-progression survival than non-FHRMM patients, underscoring the urgency of early risk identification. Among FHRMM patients, receipt of ASCT and high treatment intensity were associated with improved rwPFS. These findings highlight the potential for clinical and social determinants of health data to refine prognostic models beyond cytogenetic risk alone, with implications for treatment intensification strategies and clinical trial enrollment.
DISCLOSURES
Amy E. Pierre, MSN, ANP-BC: APSHO board - Consultancy (Includes expert testimony); Myeloma Resource Center - Consultancy (Includes expert testimony); International Myeloma Foundation Nurse Leadership Board - Consultancy (Includes expert testimony); Flatiron Health, Inc. - Current Employment